Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07499999 · ClinicalTrials.gov registry record · Phase 2
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT07499999 is a Phase 2 study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 140 participants.
The verdict
NCT07499999, a Phase 2 study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer. The names of the study drugs involved in this study are: * Exemestane (a type of steroidal aromatase inhibitor) * Tamoxifen (a type of selective estrogen receptor modulator)
Interventions
- DRUG Tamoxifen
- DRUG Exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-09-09 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07499999
The ClinicalTrials.gov registry entry for NCT07499999 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT07499999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07499999 about?
NCT07499999 is a clinical study titled "Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer". The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer. The names of the study drugs involved in this study are: * Exemestane (a type of steroidal aromatase inhibitor) * Tamoxif...
What is the current status of trial NCT07499999?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2026-09-09. Estimated completion is 2028-08-31.
What interventions are being tested in trial NCT07499999?
The interventions under investigation include: Tamoxifen (DRUG), Exemestane (DRUG).
Who is sponsoring clinical trial NCT07499999?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.